SADS Experts Insights Webinar - Exploring Solid Bioscience's Gene Therapy for CPVT

Описание: This webinar brought together the Canadian SADS Foundation and Solid Biosciences for an in depth look at the potential of gene therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The session focused on Solid’s investigational program evaluating SGT 501, an AAV based gene therapy designed to address the underlying genetic cause of CPVT.

The presentation highlighted how SGT 501 delivers a functional, codon optimized version of the CASQ2 gene to heart muscle cells, with the goal of helping stabilize calcium handling within the cell. The session also introduced the ARTEMIS Phase 1b clinical trial, a multicenter, open label, dose finding study testing a single IV infusion of SGT 501 with long term follow up. Information was also shared about regulatory progress, including FDA IND clearance and Health Canada CTA approval, along with Orphan Drug and Rare Pediatric Disease Designations.

Speakers included Dr. Gabriel Books, MD, Chief Medical Officer at Solid Biosciences, who leads the company’s clinical development programs, and Seth Rotberg, Senior Manager of Patient Advocacy, who works to ensure the patient community remains central to Solid’s efforts.

This webinar serves as an accessible resource for individuals and families affected by CPVT, as well as anyone interested in emerging gene therapy research within the inherited arrhythmia community.

If this content supports you or someone you love, consider liking the video, sharing it with others in the CPVT or inherited arrhythmia community, and subscribing to stay connected with future educational sessions from the Canadian SADS Foundation.

#CPVT
#GeneTherapy
#SADS
#CanadianSADSFoundation
#InheritedArrhythmias
#RareDisease
#CardiacResearch
#HeartRhythm
#PatientAdvocacy
#ClinicalTrials
#SolidBiosciences
#ArrhythmiaAwareness
#HeartHealth